Zana selected for Protechting Program in Portugal to Validate Voice Biomarker Technology
Zana proudly announces its selection for the Protechting Program, a global innovation initiative supported by Fidelidade, Fosun, and Luz Saúde. This provides an opportunity for a unique test bed to validate Zana’s voice biomarker technology with partners such as Hospital Luz Saúde, Portugal’s premier private health group.
Protechting focuses on fostering transformative solutions in Insurtech, Healthtech, and AI technologies, offering startups opportunities to collaborate with major industry players, develop pilots, and secure funding. Selected startups also have the chance to explore global partnerships, including a strategic visit to China.
Out of over 300 applicants, Zana was chosen to collaborate with top players in healthcare and insurance. This milestone recognizes Zana's leadership in developing voice-based AI solutions for health monitoring and chronic disease management.
As part of the program, Zana will work with healthcare and innovation experts to validate its innovative voice-to-health platform. The device-agnostic solution platform analyzes speech to detect health deterioration in conditions like Heart Failure and COPD, offering a non-invasive alternative to costly or subjective diagnostics like spirometry and implantable devices.
Zana's platform offers:
- Objective, real-time monitoring of health deterioration.
- Proactive care through timely interventions that reduce hospitalizations.
- Improved patient engagement with conversational AI and daily check-ins, driving adherence.
With the opportunity to collaborate with industry leaders and validate its groundbreaking technology, Zana is poised to redefine chronic disease management and create meaningful impact in the healthcare landscape.
